View ValuationMach7 Technologies 将来の成長Future 基準チェック /06Mach7 Technologies利益と収益がそれぞれ年間22%と7.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-23.8% 20.1%なると予測されています。主要情報22.0%収益成長率20.13%EPS成長率Healthcare Services 収益成長22.3%収益成長率7.3%将来の株主資本利益率-23.76%アナリストカバレッジLow最終更新日10 May 2026今後の成長に関する最新情報お知らせ • Jul 10+ 1 more updateMach7 Technologies Limited Provides Preliminary Unaudited Earnings Guidance for the Year Ended June 30, 2025Mach7 Technologies Limited provides preliminary unaudited earnings guidance for the year ended June 30, 2025. For the period, revenue is expected to finalize at approximately AUD 33 million to AUD 34 million in line with fiscal year 2025 guidance for revenue growth of 15-25% (AUD 33 million to AUD 36 million). This reflected strong growth in recurring revenue of approximately 20%. Contracted Annual Recurring Revenue is expected to finalize at approximately AUD 30 million to AUD 31 million, slightly below fiscal year 2025 guidance for CARR growth of 15-25% (AUD 32 million to AUD 35 million). OPEX growth will be less than revenue growth in line with fiscal year 2025 guidance.お知らせ • Jan 28Mach7 Technologies Limited Provides Revenue Guidance for the Year 2023Mach7 Technologies Limited provided revenue guidance for the year 2023. The company expects +20% revenue growth in fiscal year 2023, underpinned by a healthy pipeline and the recognition of revenue from the Trinity Health and Adventist Health sales orders as Mach7's software progressively goes live. Approximately 80-85% of the TCV associated with these contracts is yet to be recognised as revenue. At approximately 70% towards its goal, Mach7 remains confident of achieving its fiscal year 2023 sales order forecast of at least $36 million, which represents a 20% increase on the fiscal year 2022 target of $30 million and +8% on the $33.2 million achieved.すべての更新を表示Recent updatesお知らせ • Apr 21Mach7 Technologies Limited to Report Q3, 2026 Results on Apr 24, 2026Mach7 Technologies Limited announced that they will report Q3, 2026 results at 4:12 PM, AUS Eastern Standard Time on Apr 24, 2026お知らせ • Jan 22Mach7 Technologies Limited to Report Q2, 2026 Results on Jan 30, 2026Mach7 Technologies Limited announced that they will report Q2, 2026 results on Jan 30, 2026お知らせ • Oct 23Mach7 Technologies Limited to Report Q1, 2026 Results on Oct 31, 2025Mach7 Technologies Limited announced that they will report Q1, 2026 results on Oct 31, 2025お知らせ • Oct 02Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2025Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2025.お知らせ • Aug 08Mach7 Technologies Limited to Report Fiscal Year 2025 Results on Aug 27, 2025Mach7 Technologies Limited announced that they will report fiscal year 2025 results on Aug 27, 2025お知らせ • Jul 10+ 1 more updateMach7 Technologies Limited Provides Preliminary Unaudited Earnings Guidance for the Year Ended June 30, 2025Mach7 Technologies Limited provides preliminary unaudited earnings guidance for the year ended June 30, 2025. For the period, revenue is expected to finalize at approximately AUD 33 million to AUD 34 million in line with fiscal year 2025 guidance for revenue growth of 15-25% (AUD 33 million to AUD 36 million). This reflected strong growth in recurring revenue of approximately 20%. Contracted Annual Recurring Revenue is expected to finalize at approximately AUD 30 million to AUD 31 million, slightly below fiscal year 2025 guidance for CARR growth of 15-25% (AUD 32 million to AUD 35 million). OPEX growth will be less than revenue growth in line with fiscal year 2025 guidance.お知らせ • Apr 14Mach7 Technologies Limited to Report Q3, 2025 Results on Apr 29, 2025Mach7 Technologies Limited announced that they will report Q3, 2025 results on Apr 29, 2025お知らせ • Feb 28Mach7 Technologies Announces Product Launch of the Eunity Diagnostic Image Viewer Using Aws HealthimagingMach7 Technologies announced a breakthrough in medical imaging access, performance, and cloud enablement with the release of its eUnity Enterprise Diagnostic Viewer, which uses AWS HealthImaging. The release marks a major milestone for Mach7 in its continuing goal of delivering new, impactful offerings to the Healthcare IT sector. Mach7 is a part of the AWS Partner Network (APN), a global community that leverages programs, expertise, and resources to build, market, and sell customer offerings with smart integration to the cloud. The release is a significant innovation with advanced cloud capabilities that allow clinicians to have fast access to patient studies across the healthcare enterprise regardless of acquisition or data source. Key benefits: One visualization experience with the eUnity Zero Footprint Diagnostic Enterprise Viewer; Leverage High-Throughput JPEG 2000 (HTJ2K) utilized with AWS HealthImaging data stores; Federation of multiple archive locations including local storage and multiple AWS HealthImaging data stores. At petabyte scale, data transfer speeds equal to or exceeding traditional local storage models at petabyte scale, using AWS HealthImaging; Allows full control of data to support customized workflows, clinical research, and artificial intelligence (AI) modeling; The ability to segment studies for various reading groups and practices and build privilege-based access strategies for different user groups; Utilize current reading worklist to leverage current IT investments; All images are available from local or cloud data stores with no sacrifice in performance with full diagnostic image quality at sub-second latency. eUnity, using AWS HealthImaging, creates a powerful diagnostic imaging solution for clinicians and IT staff that enables automated, efficient workflows, vast scalability, and cost savings.お知らせ • Jan 31Mach7 Technologies Limited to Report First Half, 2025 Results on Feb 27, 2025Mach7 Technologies Limited announced that they will report first half, 2025 results on Feb 27, 2025お知らせ • Jan 30Mach7 Technologies Limited (ASX:M7T) announces an Equity Buyback for 24,124,104 shares, representing 10% for AUD 5 million.Mach7 Technologies Limited (ASX:M7T) announces a share repurchase program. Under the program, the company will repurchase up to 24,124,104 shares, representing 10% of its issued share capital, for AUD 5 million. The shares will be repurchased at the price no more than 5% above the volume weighted average price of company's shares over the five trading days prior to purchase. The shares repurchased will be cancelled. The program is valid till February 3, 2026. As of January 30, 2025, there are 241,241,047 outstanding shares.お知らせ • Jan 21Mach7 Technologies Limited to Report Q2, 2025 Results on Jan 31, 2025Mach7 Technologies Limited announced that they will report Q2, 2025 results on Jan 31, 2025お知らせ • Nov 12Mach7 Technologies Introduces UnityVue, A Next-Generation Radiology Reading Solution with Groundbreaking CapabilitiesMach7 Technologies announced the formal launch of UnityVue, a landmark radiology software platform developed in partnership with NewVue. UnityVue is a pioneering solution which integrates Mach7's well-renown eUnity Enterprise Diagnostic Viewer (eUnity) with NewVue's revolutionary EmpowerSuite Workflow Orchestrator, delivering a comprehensive software platform designed to improve radiology reading workflows. UnityVue consolidates radiology workflows by seamlessly integrating image viewing and worklist management. This cloud-based solution offers radiologists a powerful platform for task prioritization, AI-driven data aggregation, and enhanced diagnostic workflow—all from a single interface. UnityVue's ability to dynamically curate worklists and automate data normalization enhances productivity while reducing administrative burden. UnityVue's key features include cloud-based image access, real-time AI-driven workflow orchestration, automated data normalization, and a unified interface for radiologists to perform their tasks efficiently. With its zero-footprint design, UnityVue allows radiologists to access critical information from any location, enhancing productivity while reducing administrative complexity. Through the launch of UnityVue, Mach7 customers have a future proof, all-in-one solution that not only meets the current demands of radiologists but also anticipates future needs. By solving these critical challenges, healthcare organizations can deploy a platform that enhances job satisfaction for radiologists, improves patient care, and drives better business outcomes. Key Benefits: For Independent Delivery Networks: Unifying PACS: Integrates multiple PACS systems into a single platform, simplifying workflows and reducing inefficiencies. Gradual Cloud Migration: IDNs can migrate to the cloud incrementally, preserving existing systems while modernizing infrastructure. Disaster Recovery: Cloud-based continuity ensures radiologists can continue working during local system outages. Reduced IT Complexity: The zero-footprint design eliminates on-site server requirements and minimizes maintenance.お知らせ • Oct 11Mach7 Technologies Limited to Report Q1, 2025 Results on Oct 31, 2024Mach7 Technologies Limited announced that they will report Q1, 2025 results on Oct 31, 2024お知らせ • Oct 03Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2024Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2024.お知らせ • Jul 12Mach7 Technologies Limited to Report Fiscal Year 2024 Results on Aug 28, 2024Mach7 Technologies Limited announced that they will report fiscal year 2024 results on Aug 28, 2024お知らせ • Jul 10Mach7 Technologies Limited to Report Q4, 2024 Results on Jul 30, 2024Mach7 Technologies Limited announced that they will report Q4, 2024 results on Jul 30, 2024お知らせ • Apr 08Mach7 Technologies Limited to Report Q3, 2024 Results on Apr 24, 2024Mach7 Technologies Limited announced that they will report Q3, 2024 results on Apr 24, 2024お知らせ • Feb 15Mach7 Technologies Limited to Report First Half, 2024 Results on Feb 29, 2024Mach7 Technologies Limited announced that they will report first half, 2024 results on Feb 29, 2024お知らせ • Jan 23Mach7 Technologies Limited to Report Q2, 2024 Results on Jan 31, 2024Mach7 Technologies Limited announced that they will report Q2, 2024 results on Jan 31, 2024お知らせ • Nov 18Mach7 Technologies Limited Appoints Rebecca Thompson as DirectorMach7 Technologies Limited announced appointment of Rebecca Thompson as director. Date of appointment is 16 November 2023.お知らせ • Oct 23Mach7 Technologies Limited to Report Q1, 2024 Results on Oct 31, 2023Mach7 Technologies Limited announced that they will report Q1, 2024 results on Oct 31, 2023お知らせ • Sep 22Mach7 Technologies Limited Announces Board Changes, Effective 16 November 2023Mach7 Technologies Limited announced that Mr. Philippe Houssiau will retire as Non-Executive Director of the company, effective from the close of the Company's Annual General Meeting on 16 November 2023 and that Ms. Rebecca Thompson has agreed to join the Mach7 Board as an independent Non-Executive Director, following the conclusion of the Company's Annual General Meeting on 16 November 2023. Mr. Houssiau joined the Mach7 Board in January 2021 as an independent Non-Executive Director and has served on the Company's Remuneration and Nomination Committee. As a part of the recently announced Board renewal process Ms Thompson will be joining the Board as a Non-Executive Director. Ms Thompson has deep experience in financial markets with senior roles at global investment banks, most recently at J.P. Morgan, and with listed companies over her 30-year career to date. Since mid-2022 and until her recent appointment as head of investor relations at CSR Limited, Rebecca was a consultant to Mach7. Apart from providing Rebecca with a strong understanding of the Mach7 business and its market dynamics, the relationship has demonstrated Rebecca's professionalism, commercial acumen, compatibility and sound judgement. Rebecca's professional experience spans the property, resources, fintech and charitable sectors with a strong focus on sustainability and ESG. She holds a Bachelor Degree in Economics from the University of Sydney and has a graduate qualification in finance and investment.お知らせ • Aug 28Mach7 Technologies Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Mach7 Technologies Limited announced that they will report fiscal year 2023 results on Aug 31, 2023お知らせ • Aug 11Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023.お知らせ • Jul 28Mach7 Technologies Limited to Report Q4, 2023 Results on Jul 31, 2023Mach7 Technologies Limited announced that they will report Q4, 2023 results on Jul 31, 2023お知らせ • Feb 01Mach7 Technologies Limited Announces Change of Company SecretaryMach7 Technologies Limited announced the appointment of Mr. Tony Panther as Company Secretary, effective 1 February 2023, to replace Ms. Veronique Morgan-Smith, following team reassignments at Vistra Australia, the Company's provider of secretarial and corporate compliance services. Mr. Panther is a Chartered Accountant with over 30 years' experience in a variety of fields. Following completion of university commerce and law degrees he worked as an external auditor with a major international chartered accounting firm and has progressed to a range of internal audit, compliance, senior finance, and company secretarial roles with a number of ASX-listed and unlisted public companies and professional services firms, covering financial services, utilities, biotech, IT services, mineral exploration and environmental technologies. He specialises in financial reporting and company secretarial practice.お知らせ • Jan 28Mach7 Technologies Limited Provides Revenue Guidance for the Year 2023Mach7 Technologies Limited provided revenue guidance for the year 2023. The company expects +20% revenue growth in fiscal year 2023, underpinned by a healthy pipeline and the recognition of revenue from the Trinity Health and Adventist Health sales orders as Mach7's software progressively goes live. Approximately 80-85% of the TCV associated with these contracts is yet to be recognised as revenue. At approximately 70% towards its goal, Mach7 remains confident of achieving its fiscal year 2023 sales order forecast of at least $36 million, which represents a 20% increase on the fiscal year 2022 target of $30 million and +8% on the $33.2 million achieved.業績と収益の成長予測OTCPK:TDMM.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202834-5-2-126/30/202730-8-5-326/30/202628-10-7-4212/31/202530-10-10N/A9/30/202532-8-10N/A6/30/202534-6-11N/A3/31/202534-6-11N/A12/31/202434-501N/A9/30/202431-712N/A6/30/202429-833N/A3/31/202428-733N/A12/31/202327-622N/A9/30/202329-300N/A6/30/202330-1-3-3N/A3/31/202329-2-2-1N/A12/31/202228-400N/A9/30/202227-433N/A6/30/202226-466N/A3/31/202226-356N/A12/31/202126-355N/A9/30/202123-633N/A6/30/202119-911N/A3/31/202118-911N/A12/31/202017-800N/A9/30/202018-423N/A6/30/202019055N/A3/31/202017-133N/A12/31/201915-211N/A9/30/201912-5N/A-1N/A6/30/20199-7N/A-3N/A3/31/20199-7N/A-4N/A12/31/20188-6N/A-4N/A9/30/20188-5N/A-3N/A6/30/20189-5N/A-2N/A3/31/20189-11N/A-2N/A12/31/20179-17N/A-3N/A9/30/201710-17N/A-4N/A6/30/201710-18N/A-5N/A3/31/20178-16N/A-5N/A12/31/20166-15N/A-4N/A9/30/20164-14N/A-4N/A6/30/20162-13N/A-3N/A12/31/20158-3N/AN/AN/A6/30/20150-7N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: TDMM.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: TDMM.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: TDMM.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: TDMM.Fの収益 ( 7.3% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: TDMM.Fの収益 ( 7.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: TDMM.F 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 02:12終値2026/05/21 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mach7 Technologies Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Madeleine WilliamsCanaccord GenuityShane StoreyCanaccord GenuityScott PowerCGS International5 その他のアナリストを表示
お知らせ • Jul 10+ 1 more updateMach7 Technologies Limited Provides Preliminary Unaudited Earnings Guidance for the Year Ended June 30, 2025Mach7 Technologies Limited provides preliminary unaudited earnings guidance for the year ended June 30, 2025. For the period, revenue is expected to finalize at approximately AUD 33 million to AUD 34 million in line with fiscal year 2025 guidance for revenue growth of 15-25% (AUD 33 million to AUD 36 million). This reflected strong growth in recurring revenue of approximately 20%. Contracted Annual Recurring Revenue is expected to finalize at approximately AUD 30 million to AUD 31 million, slightly below fiscal year 2025 guidance for CARR growth of 15-25% (AUD 32 million to AUD 35 million). OPEX growth will be less than revenue growth in line with fiscal year 2025 guidance.
お知らせ • Jan 28Mach7 Technologies Limited Provides Revenue Guidance for the Year 2023Mach7 Technologies Limited provided revenue guidance for the year 2023. The company expects +20% revenue growth in fiscal year 2023, underpinned by a healthy pipeline and the recognition of revenue from the Trinity Health and Adventist Health sales orders as Mach7's software progressively goes live. Approximately 80-85% of the TCV associated with these contracts is yet to be recognised as revenue. At approximately 70% towards its goal, Mach7 remains confident of achieving its fiscal year 2023 sales order forecast of at least $36 million, which represents a 20% increase on the fiscal year 2022 target of $30 million and +8% on the $33.2 million achieved.
お知らせ • Apr 21Mach7 Technologies Limited to Report Q3, 2026 Results on Apr 24, 2026Mach7 Technologies Limited announced that they will report Q3, 2026 results at 4:12 PM, AUS Eastern Standard Time on Apr 24, 2026
お知らせ • Jan 22Mach7 Technologies Limited to Report Q2, 2026 Results on Jan 30, 2026Mach7 Technologies Limited announced that they will report Q2, 2026 results on Jan 30, 2026
お知らせ • Oct 23Mach7 Technologies Limited to Report Q1, 2026 Results on Oct 31, 2025Mach7 Technologies Limited announced that they will report Q1, 2026 results on Oct 31, 2025
お知らせ • Oct 02Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2025Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2025.
お知らせ • Aug 08Mach7 Technologies Limited to Report Fiscal Year 2025 Results on Aug 27, 2025Mach7 Technologies Limited announced that they will report fiscal year 2025 results on Aug 27, 2025
お知らせ • Jul 10+ 1 more updateMach7 Technologies Limited Provides Preliminary Unaudited Earnings Guidance for the Year Ended June 30, 2025Mach7 Technologies Limited provides preliminary unaudited earnings guidance for the year ended June 30, 2025. For the period, revenue is expected to finalize at approximately AUD 33 million to AUD 34 million in line with fiscal year 2025 guidance for revenue growth of 15-25% (AUD 33 million to AUD 36 million). This reflected strong growth in recurring revenue of approximately 20%. Contracted Annual Recurring Revenue is expected to finalize at approximately AUD 30 million to AUD 31 million, slightly below fiscal year 2025 guidance for CARR growth of 15-25% (AUD 32 million to AUD 35 million). OPEX growth will be less than revenue growth in line with fiscal year 2025 guidance.
お知らせ • Apr 14Mach7 Technologies Limited to Report Q3, 2025 Results on Apr 29, 2025Mach7 Technologies Limited announced that they will report Q3, 2025 results on Apr 29, 2025
お知らせ • Feb 28Mach7 Technologies Announces Product Launch of the Eunity Diagnostic Image Viewer Using Aws HealthimagingMach7 Technologies announced a breakthrough in medical imaging access, performance, and cloud enablement with the release of its eUnity Enterprise Diagnostic Viewer, which uses AWS HealthImaging. The release marks a major milestone for Mach7 in its continuing goal of delivering new, impactful offerings to the Healthcare IT sector. Mach7 is a part of the AWS Partner Network (APN), a global community that leverages programs, expertise, and resources to build, market, and sell customer offerings with smart integration to the cloud. The release is a significant innovation with advanced cloud capabilities that allow clinicians to have fast access to patient studies across the healthcare enterprise regardless of acquisition or data source. Key benefits: One visualization experience with the eUnity Zero Footprint Diagnostic Enterprise Viewer; Leverage High-Throughput JPEG 2000 (HTJ2K) utilized with AWS HealthImaging data stores; Federation of multiple archive locations including local storage and multiple AWS HealthImaging data stores. At petabyte scale, data transfer speeds equal to or exceeding traditional local storage models at petabyte scale, using AWS HealthImaging; Allows full control of data to support customized workflows, clinical research, and artificial intelligence (AI) modeling; The ability to segment studies for various reading groups and practices and build privilege-based access strategies for different user groups; Utilize current reading worklist to leverage current IT investments; All images are available from local or cloud data stores with no sacrifice in performance with full diagnostic image quality at sub-second latency. eUnity, using AWS HealthImaging, creates a powerful diagnostic imaging solution for clinicians and IT staff that enables automated, efficient workflows, vast scalability, and cost savings.
お知らせ • Jan 31Mach7 Technologies Limited to Report First Half, 2025 Results on Feb 27, 2025Mach7 Technologies Limited announced that they will report first half, 2025 results on Feb 27, 2025
お知らせ • Jan 30Mach7 Technologies Limited (ASX:M7T) announces an Equity Buyback for 24,124,104 shares, representing 10% for AUD 5 million.Mach7 Technologies Limited (ASX:M7T) announces a share repurchase program. Under the program, the company will repurchase up to 24,124,104 shares, representing 10% of its issued share capital, for AUD 5 million. The shares will be repurchased at the price no more than 5% above the volume weighted average price of company's shares over the five trading days prior to purchase. The shares repurchased will be cancelled. The program is valid till February 3, 2026. As of January 30, 2025, there are 241,241,047 outstanding shares.
お知らせ • Jan 21Mach7 Technologies Limited to Report Q2, 2025 Results on Jan 31, 2025Mach7 Technologies Limited announced that they will report Q2, 2025 results on Jan 31, 2025
お知らせ • Nov 12Mach7 Technologies Introduces UnityVue, A Next-Generation Radiology Reading Solution with Groundbreaking CapabilitiesMach7 Technologies announced the formal launch of UnityVue, a landmark radiology software platform developed in partnership with NewVue. UnityVue is a pioneering solution which integrates Mach7's well-renown eUnity Enterprise Diagnostic Viewer (eUnity) with NewVue's revolutionary EmpowerSuite Workflow Orchestrator, delivering a comprehensive software platform designed to improve radiology reading workflows. UnityVue consolidates radiology workflows by seamlessly integrating image viewing and worklist management. This cloud-based solution offers radiologists a powerful platform for task prioritization, AI-driven data aggregation, and enhanced diagnostic workflow—all from a single interface. UnityVue's ability to dynamically curate worklists and automate data normalization enhances productivity while reducing administrative burden. UnityVue's key features include cloud-based image access, real-time AI-driven workflow orchestration, automated data normalization, and a unified interface for radiologists to perform their tasks efficiently. With its zero-footprint design, UnityVue allows radiologists to access critical information from any location, enhancing productivity while reducing administrative complexity. Through the launch of UnityVue, Mach7 customers have a future proof, all-in-one solution that not only meets the current demands of radiologists but also anticipates future needs. By solving these critical challenges, healthcare organizations can deploy a platform that enhances job satisfaction for radiologists, improves patient care, and drives better business outcomes. Key Benefits: For Independent Delivery Networks: Unifying PACS: Integrates multiple PACS systems into a single platform, simplifying workflows and reducing inefficiencies. Gradual Cloud Migration: IDNs can migrate to the cloud incrementally, preserving existing systems while modernizing infrastructure. Disaster Recovery: Cloud-based continuity ensures radiologists can continue working during local system outages. Reduced IT Complexity: The zero-footprint design eliminates on-site server requirements and minimizes maintenance.
お知らせ • Oct 11Mach7 Technologies Limited to Report Q1, 2025 Results on Oct 31, 2024Mach7 Technologies Limited announced that they will report Q1, 2025 results on Oct 31, 2024
お知らせ • Oct 03Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2024Mach7 Technologies Limited, Annual General Meeting, Nov 28, 2024.
お知らせ • Jul 12Mach7 Technologies Limited to Report Fiscal Year 2024 Results on Aug 28, 2024Mach7 Technologies Limited announced that they will report fiscal year 2024 results on Aug 28, 2024
お知らせ • Jul 10Mach7 Technologies Limited to Report Q4, 2024 Results on Jul 30, 2024Mach7 Technologies Limited announced that they will report Q4, 2024 results on Jul 30, 2024
お知らせ • Apr 08Mach7 Technologies Limited to Report Q3, 2024 Results on Apr 24, 2024Mach7 Technologies Limited announced that they will report Q3, 2024 results on Apr 24, 2024
お知らせ • Feb 15Mach7 Technologies Limited to Report First Half, 2024 Results on Feb 29, 2024Mach7 Technologies Limited announced that they will report first half, 2024 results on Feb 29, 2024
お知らせ • Jan 23Mach7 Technologies Limited to Report Q2, 2024 Results on Jan 31, 2024Mach7 Technologies Limited announced that they will report Q2, 2024 results on Jan 31, 2024
お知らせ • Nov 18Mach7 Technologies Limited Appoints Rebecca Thompson as DirectorMach7 Technologies Limited announced appointment of Rebecca Thompson as director. Date of appointment is 16 November 2023.
お知らせ • Oct 23Mach7 Technologies Limited to Report Q1, 2024 Results on Oct 31, 2023Mach7 Technologies Limited announced that they will report Q1, 2024 results on Oct 31, 2023
お知らせ • Sep 22Mach7 Technologies Limited Announces Board Changes, Effective 16 November 2023Mach7 Technologies Limited announced that Mr. Philippe Houssiau will retire as Non-Executive Director of the company, effective from the close of the Company's Annual General Meeting on 16 November 2023 and that Ms. Rebecca Thompson has agreed to join the Mach7 Board as an independent Non-Executive Director, following the conclusion of the Company's Annual General Meeting on 16 November 2023. Mr. Houssiau joined the Mach7 Board in January 2021 as an independent Non-Executive Director and has served on the Company's Remuneration and Nomination Committee. As a part of the recently announced Board renewal process Ms Thompson will be joining the Board as a Non-Executive Director. Ms Thompson has deep experience in financial markets with senior roles at global investment banks, most recently at J.P. Morgan, and with listed companies over her 30-year career to date. Since mid-2022 and until her recent appointment as head of investor relations at CSR Limited, Rebecca was a consultant to Mach7. Apart from providing Rebecca with a strong understanding of the Mach7 business and its market dynamics, the relationship has demonstrated Rebecca's professionalism, commercial acumen, compatibility and sound judgement. Rebecca's professional experience spans the property, resources, fintech and charitable sectors with a strong focus on sustainability and ESG. She holds a Bachelor Degree in Economics from the University of Sydney and has a graduate qualification in finance and investment.
お知らせ • Aug 28Mach7 Technologies Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Mach7 Technologies Limited announced that they will report fiscal year 2023 results on Aug 31, 2023
お知らせ • Aug 11Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023.
お知らせ • Jul 28Mach7 Technologies Limited to Report Q4, 2023 Results on Jul 31, 2023Mach7 Technologies Limited announced that they will report Q4, 2023 results on Jul 31, 2023
お知らせ • Feb 01Mach7 Technologies Limited Announces Change of Company SecretaryMach7 Technologies Limited announced the appointment of Mr. Tony Panther as Company Secretary, effective 1 February 2023, to replace Ms. Veronique Morgan-Smith, following team reassignments at Vistra Australia, the Company's provider of secretarial and corporate compliance services. Mr. Panther is a Chartered Accountant with over 30 years' experience in a variety of fields. Following completion of university commerce and law degrees he worked as an external auditor with a major international chartered accounting firm and has progressed to a range of internal audit, compliance, senior finance, and company secretarial roles with a number of ASX-listed and unlisted public companies and professional services firms, covering financial services, utilities, biotech, IT services, mineral exploration and environmental technologies. He specialises in financial reporting and company secretarial practice.
お知らせ • Jan 28Mach7 Technologies Limited Provides Revenue Guidance for the Year 2023Mach7 Technologies Limited provided revenue guidance for the year 2023. The company expects +20% revenue growth in fiscal year 2023, underpinned by a healthy pipeline and the recognition of revenue from the Trinity Health and Adventist Health sales orders as Mach7's software progressively goes live. Approximately 80-85% of the TCV associated with these contracts is yet to be recognised as revenue. At approximately 70% towards its goal, Mach7 remains confident of achieving its fiscal year 2023 sales order forecast of at least $36 million, which represents a 20% increase on the fiscal year 2022 target of $30 million and +8% on the $33.2 million achieved.